Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2014 1
2016 3
2017 5
2018 6
2019 6
2020 14
2021 11
2022 4
2023 4
2024 11
2025 5
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: 5C4.B8
Page 1
Preclinical Evaluation of DB-1419, a Novel Bifunctional and Bispecific Anti-B7-H3 × PD-L1 Antibody-Drug Conjugate.
Li C, Yao J, Yang J, Zhang Y, Qiu Y, Zhu Z, Hua H. Li C, et al. Clin Cancer Res. 2025 Aug 14;31(16):3581-3593. doi: 10.1158/1078-0432.CCR-25-0634. Clin Cancer Res. 2025. PMID: 40499141 Free PMC article.
The mechanisms of action behind the efficacy, pharmacokinetics in cynomolgus monkeys, and the safety profiles in vitro and in cynomolgus monkeys were also explored. ...Furthermore, DB-1419 has driven a robust antitumor response in immunocompetent PDX; the blockade o …
The mechanisms of action behind the efficacy, pharmacokinetics in cynomolgus monkeys, and the safety profiles in vitro and in cyno …
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
Ishiguro T, Sano Y, Komatsu SI, Kamata-Sakurai M, Kaneko A, Kinoshita Y, Shiraiwa H, Azuma Y, Tsunenari T, Kayukawa Y, Sonobe Y, Ono N, Sakata K, Fujii T, Miyazaki Y, Noguchi M, Endo M, Harada A, Frings W, Fujii E, Nanba E, Narita A, Sakamoto A, Wakabayashi T, Konishi H, Segawa H, Igawa T, Tsushima T, Mutoh H, Nishito Y, Takahashi M, Stewart L, ElGabry E, Kawabe Y, Ishigai M, Chiba S, Aoki M, Hattori K, Nezu J. Ishiguro T, et al. Sci Transl Med. 2017 Oct 4;9(410):eaal4291. doi: 10.1126/scitranslmed.aal4291. Sci Transl Med. 2017. PMID: 28978751
Immune monitoring revealed that ERY974 converted the poorly inflamed tumor microenvironment to a highly inflamed microenvironment. Toxicology studies in cynomolgus monkeys showed transient cytokine elevation, but this was manageable and reversible. ...
Immune monitoring revealed that ERY974 converted the poorly inflamed tumor microenvironment to a highly inflamed microenvironment. Toxicolog …
In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, Singh S, Wong S, Garner N, Leblanc H, Bunch RT, Blanset D, Selby MJ, Korman AJ. Wang C, et al. Cancer Immunol Res. 2014 Sep;2(9):846-56. doi: 10.1158/2326-6066.CIR-14-0040. Epub 2014 May 28. Cancer Immunol Res. 2014. PMID: 24872026
Nivolumab treatment did not induce adverse immune-related events when given to cynomolgus macaques at high concentrations, independent of circulating anti-nivolumab antibodies where observed. ...
Nivolumab treatment did not induce adverse immune-related events when given to cynomolgus macaques at high concentrations, independen …
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody.
Ke H, Yang T, Zhang F, Chen C, Wang J, Liu J, An X, Xiong L, He X, Zhang L, Li QX. Ke H, et al. Sci Rep. 2024 Nov 15;14(1):28201. doi: 10.1038/s41598-024-79865-3. Sci Rep. 2024. PMID: 39548213 Free PMC article.
HX009 caused little cytokine-release in human peripheral blood mononuclear cells. HX009 cross-species binds to cynomolgus monkey PD1/CD47 but not to rodents, making cynomolgus monkeys the choice of species to investigate the pharmacokinetics (PK) and t …
HX009 caused little cytokine-release in human peripheral blood mononuclear cells. HX009 cross-species binds to cynomolgus monkey …
Pharmacological and structural characterization of vibostolimab, a novel anti-TIGIT blocking antibody for cancer immunotherapy.
Fischmann TO, Malashock D, Ahn E, Wang H, Pradhan K, Grein J, Chakravorty S, Bahmanjah S, Ban D, Chien E, Hsieh M, Mayhood T, Yuan J, Wong JC, Beaumont M, Baker J, McCoy MA, Cai M, Wilson D, Blumenschein W, Williams SMG, Fayadat-Dilman L, Seghezzi W, Keenan T, Han JH. Fischmann TO, et al. J Immunother Cancer. 2025 Aug 18;13(8):e008972. doi: 10.1136/jitc-2024-008972. J Immunother Cancer. 2025. PMID: 40829901 Free PMC article.
Vibostolimab was developed based on its specific binding property to the human and cynomolgus monkey TIGIT protein and its functional blocking activity of the TIGIT:CD155 interaction. ...
Vibostolimab was developed based on its specific binding property to the human and cynomolgus monkey TIGIT protein and its fun …
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers.
Champiat S, Garralda E, Galvao V, Cassier PA, Gomez-Roca C, Korakis I, Grell P, Naing A, LoRusso P, Mikyskova R, Podzimkova N, Reinis M, Ouali K, Schoenenberger A, Kiemle-Kallee J, Tillmanns S, Sachse R, Moebius U, Spisek R, Bechard D, Jelinkova LP, Adkins I, Marabelle A. Champiat S, et al. Cell Rep Med. 2025 Feb 18;6(2):101967. doi: 10.1016/j.xcrm.2025.101967. Epub 2025 Feb 10. Cell Rep Med. 2025. PMID: 39933529 Free PMC article. Clinical Trial.
Nanrilkefusp alfa (nanril; SOT101) is an interleukin (IL)-15 receptor betagamma superagonist that stimulates natural killer (NK) and CD8(+) T cells, thereby promoting an innate and adaptive anti-tumor inflammatory microenvironment in mouse tumor models either in monotherapy or co …
Nanrilkefusp alfa (nanril; SOT101) is an interleukin (IL)-15 receptor betagamma superagonist that stimulates natural killer (NK) and CD8(+) …
CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity.
Sullivan KMC, Vilalta M, Ertl LS, Wang Y, Dunlap C, Ebsworth K, Zhao BN, Li S, Zeng Y, Miao Z, Fan P, Mali V, Lange C, McMurtrie D, Yang J, Lui R, Scamp R, Chhina V, Kumamoto A, Yau S, Dang T, Easterday A, Liu S, Miao S, Charo I, Schall TJ, Zhang P. Sullivan KMC, et al. PLoS One. 2023 Jun 7;18(6):e0286724. doi: 10.1371/journal.pone.0286724. eCollection 2023. PLoS One. 2023. PMID: 37285333 Free PMC article.
Cell surface PD-L1 expression recovered in MC38 tumors upon CCX559 clearance post dosing. In a cynomolgus monkey pharmacodynamic study, CCX559 increased plasma levels of soluble PD-L1. ...
Cell surface PD-L1 expression recovered in MC38 tumors upon CCX559 clearance post dosing. In a cynomolgus monkey pharmacodynam …
Generation, ex vivo expansion and safety of engineered PD1-knockout primary T cells from cynomolgus macaques.
Gao CE, Song Q, Zhang M, Li J, Miao Y, Li Z, Dong J. Gao CE, et al. Mol Immunol. 2020 Aug;124:100-108. doi: 10.1016/j.molimm.2020.05.007. Epub 2020 Jun 15. Mol Immunol. 2020. PMID: 32554100
Here, we describe a cynomolgus macaque model for studying the transfer of PD1-modified T cells. We developed the first T cell engager targeting the disruption of PD1 by electroporation of plasmids encoding sgRNA and Cas9. ...We adoptively transferred autologo …
Here, we describe a cynomolgus macaque model for studying the transfer of PD1-modified T cells. We developed the first T cell …
Translate Pharmacokinetics of PD-1/PD-L1 Monoclonal Antibodies from Cynomolgus Monkey to Human: Comparison of Different Approaches.
Chen W, Wang L, Ruan Z, Lou H, Jiang B. Chen W, et al. J Pharm Sci. 2024 Sep;113(9):2915-2921. doi: 10.1016/j.xphs.2024.07.003. Epub 2024 Jul 9. J Pharm Sci. 2024. PMID: 38986869
This study aims to predict the PK of PD-1/PD-L1 antibodies in human by scaling of monkey data. A systematic literature search of published articles on the PK of PD-1/PD-L1 antibodies in cynomolgus monkey and in human was conducted. ...The STIV method and the …
This study aims to predict the PK of PD-1/PD-L1 antibodies in human by scaling of monkey data. A systematic literature search of publ …
Selection of a PD-1 blocking antibody from a novel fully human phage display library.
Peissert F, Plüss L, Giudice AM, Ongaro T, Villa A, Elsayed A, Nadal L, Dakhel Plaza S, Scietti L, Puca E, De Luca R, Forneris F, Neri D. Peissert F, et al. Protein Sci. 2022 Dec;31(12):e4486. doi: 10.1002/pro.4486. Protein Sci. 2022. PMID: 36317676 Free PMC article.
The D12 antibody was characterized by surface plasmon resonance (SPR), cross-reacted with the Cynomolgus monkey antigen and bound to primary human T cells, as shown by flow cytometry. ...
The D12 antibody was characterized by surface plasmon resonance (SPR), cross-reacted with the Cynomolgus monkey antigen and bo …
64 results